TWiV 823: COVID-19 clinical update #86 with Dr. Daniel Griffin

In COVID-19 clinical update #86, Dr. Griffin discusses virologic features of infection in children, antibody tests should not be used to asses level of protection, test-to-stay programs in schools, FDA authorizes Moderna boosters, results of TOGETHER trial for fluvoxamine, statins and 28 day mortality, and cognitive function in patients. Hosts: Daniel Griffin and Vincent Racaniello Subscribe (free): iTunes , Google Podcasts , RSS , email Become a patron of TWiV! Links for this episode 115,000 healthcare worker deaths (Stat News) Virology features of infection in children (J Inf Dis) Antibody tests not for assessing protection (FDA) Infections in vaccinated healthcare workers (NEJM) Flawed science of antibody testing (JAMA) Test-to-stay in school (US News) Vaccination and non-COVID mortality risk (MMWR) EUA for Moderna booster (FDA) Fact sheet for use of casirivimab and imdevimab (FDA) Effect of early treatment with fluvoxamine (Lancet) Statins and 28-day mortality (J Inf Dis) Cognitive function after COVID-19 (JAMA) Routine vaccination coverage worldwide (MMWR) Letters read on TWiV 823 Timestamps by Jolene . Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]